{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-128270","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2022-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.714597+00:00","generated_at":"2026-06-21T02:35:56.337910+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Entrada receives FDA clinical hold on IND for ENTR-601-44 in Duchenne muscular dystrophy","bullets":["Clinical hold placed on IND for ENTR-601-44, a potential treatment for DMD with exon 44 skippable mutations.","FDA to provide official clinical hold letter within 30 days; Entrada will work to address concerns.","No approved therapies exist for patients with exon 44 skippable mutations.","Entrada plans to share updates after further communications with the FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-128270","json":"https://secwatch.observer/filing/0001104659-22-128270.json","markdown":"https://secwatch.observer/filing/0001104659-22-128270.md","text":"https://secwatch.observer/filing/0001104659-22-128270.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000110465922128270/0001104659-22-128270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000110465922128270/tm2233021d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T02:35:56.337910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}